Slide 1: Edwards Lifesciences Reports Second Quarter Results
NEWS RELEASE Edwards Lifesciences Reports Second Quarter Results 2026-07-23 IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported nancial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion 1, constant currency 2 sales grew 12.5% Q2
Slide 2: Transcatheter Aortic Valve Replacement (TAVR)
Increasing TMTT sales guidance: $760 to $780 million from $740 to $780 million Rea rming adjusted EPS guidance of $2.95 to $3.05, growing 17% at midpoint Expected clinical presentations at TCT: PROGRESS and CLASP IITR Expected Q4 approvals of PASCAL tricuspid indication in U.S. and next-generation P
Slide 3: Transcatheter Mitral and Tricuspid Therapies (TMTT)
September. This update has the potential to advance TAVR therapy for Medicare bene ciaries with aortic stenosis. Outside of the U.S., the company continues to see strong adoption of the SAPIEN platform. In Europe, updated ESC and EACTS guidelines are helping shape clinical discussions around earlier
Slide 4: Additional Financial Results
INSPIRIS, MITRIS and KONECT devices, which provide extended durability for patients. At the recent AATS conference, 10-year data from the COMMENCE trial, studying the long-term durability of Edwards’ best-in-class RESILIA tissue, were presented. The results showed favorable 10-year freedom from stru
Slide 5: Outlook
Cash and cash equivalents were approximately $2.9 billion as of June 30, 2026. Total debt was approximately $600 million. Edwards has approximately $1.5 billion remaining under its share repurchase authorization. Outlook Based on the company’s second quarter performance, Edwards is increasing its fu
Slide 6: Forward-looking statements
our regions, our clarity, mindset, commitment to innovation and execution driving progress, our nancial strength, our expectations regarding growth and impact on patients, our long-term evidence supporting our di erentiated SAPIEN platform, our best-in-class valve performance and long-term durabilit
Slide 7: Unaudited Consolidated Statements and Notes
trademarks are the property of their respective owners. ____________________ [1]Reported sales and diluted EPS are from continuing operations. [2]The company uses the terms “adjusted” and “constant currency” when referring to non-GAAP sales from continuing operations and sales growth information, re
Slide 8: Non-GAAP Financial Information
____________________ Note: Numbers may not calculate due to rounding. EDWARDS LIFESCIENCES CORPORATION Non-GAAP Financial Information To supplement the consolidated nancial results prepared in accordance with Generally Accepted Accounting Principles (“GAAP”), the Company uses non-GAAP historical nan
Slide 9: Non-GAAP Adjustment Descriptions
as adjusted, for the items identi ed above due to the inherent di culty in forecasting such items without unreasonable e orts. The Company is not able to provide a reconciliation of the non-GAAP guidance to comparable GAAP measures due to the unknown e ect, timing, and potential signi cance of speci
Slide 10: Unaudited Reconciliation of GAAP to Non-GAAP Financial Information
the income tax impact of these items in subsequent periods. EDWARDS LIFESCIENCES CORPORATION Unaudited Reconciliation of GAAP to Non-GAAP Financial Information (in millions, except per share and percentage data) Three Months Ended June 30, 2026 Other Gross Operating Operating Non- Net Pro t Income,
Slide 11: Reconciliation: Six Months Ended June 30
Non-GAAP adjustments:(A) (B) Certain litigation expenses — — 43.4 1.3 — — 32.9 0.06 (0.4) Amortization of intangible assets — 0.2 6.5 0.2 — — 5.0 — — Gain on remeasurement of previously held interest upon business combinations — — — — — (85.1) (73.3) (0.12) 2.0 Loss on impairment — — — — (163.6) — 1
Slide 12: Sales by Product Group and Region
GAAP 2025 Currency Sales by Product Group (YTD) - Continuing YTD 2Q YTD 2Q Growth FX Adjusted Growth Operations 2026 2025 Change Rate* Impact Sales Rate * Transcatheter Aortic Valve Replacement $ 2,455.6 $ 2,177.5 $ 278.1 12.8% $ 40.4 $ 2,217.9 10.7% Transcatheter Mitral and Tricuspid Therapies(A) 3